P850064/S056: LifePulse High Frequency Ventilator
The FDA's Center for Devices and Radiological Health completed review of a premarket approval application 180-day supplement for the LifePulse High Frequency Ventilator, product code LSZ, submitted by Bunnell, Inc. The supplement is logged under P850064/S056, and its stated reason is a labeling change covering indications, instructions, shelf life or tradename; the decision recorded is approval. The action concerns the device's Indications for Use, not a new approval of the whole system.
The approved updated IFU reads that the device is indicated for treating pediatric patients, including neonates, who require temporary ventilatory support for acute respiratory failure. The statement also assigns the clinician responsibility for determining appropriate use and for considering the patient's respiratory status and general health when setting ventilator settings. The database entry does not describe the prior IFU wording, the basis for the change, or any clinical data, so the degree of change from the earlier labeling remains unspecified.
FDA approval-order wording
The Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) has completed its review of your premarket approval application (PMA) 180-day supplement, which requested approval for an update to the Indications for Use (IFU). The approved updated IFU will read: The LifePulse High Frequency Ventilator is indicated for treating pediatric patients (including neonates) who require temporary ventilatory support for acute respiratory failure. It is the responsibility of the clinician to determine the appropriate use of the LifePulse High Frequency Ventilator. The user needs to consider the respiratory status and the general state of health of the patient in order to optimally set ventilator settings for the patients condition(s).


